Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlight key findings from the SURPASS-5 trial, noting the significant reductions in HbA1c levels and improvements in glycemic control. Phrases like 'outstanding weight loss' and 'good effect on A1c' reflect a positive sentiment, while terms such as 'great plenary' suggest that the findings are being broadly acknowledged and discussed in professional circles.
The majority of discussions indicate support for the trial's findings, with many users expressing a positive outlook towards tirzepatide's role in managing type 2 diabetes.
There is a notable excitement surrounding the publication, as participants demonstrate curiosity about the research implications and the efficacy of tirzepatide.
While not all posts delve deeply into the study, several reference specific methods and outcomes, indicating a level of engagement with the content.
Many users believe that this research carries significant implications for diabetes treatment, highlighting its potential to improve patient outcomes.
Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous tirzepatide, vs placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 wk. https://t.co/LlO1c0GpRr https://t.co/IqHycbTJAF
#tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2 #diabetes JAMA. 2022;327(6):534-545. doi:10.1001/jama.2022.0078 https://t.co/hC10azu0Py https://t.co/zNomWMcYJ3
https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes #SURPASS5trial Orgulloso de la participación de centros Españoles en esta gran innovación @SEDiabetes @LillyES https://t.co/2LldT4yKzp
Great plenary by @JohnFralick8 on the top 5 papers in GIM! Here are the take away points and links! https://t.co/IJmGoz0TSJ https://t.co/GOOtyKPpDq https://t.co/LOsck9UJ5D https://t.co/q4hGEKeQIP https://t.co/OWMshjdjlz https://t.co/fTuCBfT1iq
Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous tirzepatide, vs placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 wk. https://t.co/BFDnS4UTjX https://t.co/Hp3qoATtWG
This video explains how Tirzepatide, known as Mounjaro, works by targeting GLP-1 and GIP receptors to control blood sugar and promote weight loss, highlighting its potential for treating diabetes and obesity.
Prof Jörg Bojunga explains the optimal medication strategies for Type 2 Diabetes based on the National Guideline, discussing various drug classes and recent studies on insulin and cardiovascular outcomes.
- "In this pt with uncontrolled #diabetes, A1c 7.4, we decreased glargine by 10% [when we started tirzepatide]"
RT @BevTchangMD: SURPASS-5: tirzepatide + basal insulin vs. placebo Method: If baseline A1c<8, ⬇️long acting insulin dose by 20% at start…
RT @BevTchangMD: SURPASS-5: tirzepatide + basal insulin vs. placebo Method: If baseline A1c<8, ⬇️long acting insulin dose by 20% at start…
SURPASS-5: tirzepatide + basal insulin vs. placebo Method: If baseline A1c<8, ⬇️long acting insulin dose by 20% at start of study Result: At end of study, insulin was ⬇️11% for 15-mg tirzepatide group vs. ⬆️75% for placebo https://t.co/kmmdLyinNb 2/ https://t.co/AE4drdzqE3
RT @WKSilverstein: Great plenary by @JohnFralick8 on the top 5 papers in GIM! Here are the take away points and links! https://t.co/IJmGo…
RT @WKSilverstein: Great plenary by @JohnFralick8 on the top 5 papers in GIM! Here are the take away points and links! https://t.co/IJmGo…
RT @WKSilverstein: Great plenary by @JohnFralick8 on the top 5 papers in GIM! Here are the take away points and links! https://t.co/IJmGo…
RT @WKSilverstein: Great plenary by @JohnFralick8 on the top 5 papers in GIM! Here are the take away points and links! https://t.co/IJmGo…
RT @WKSilverstein: Great plenary by @JohnFralick8 on the top 5 papers in GIM! Here are the take away points and links! https://t.co/IJmGo…
Great plenary by @JohnFralick8 on the top 5 papers in GIM! Here are the take away points and links! https://t.co/IJmGoz0TSJ https://t.co/GOOtyKPpDq https://t.co/LOsck9UJ5D https://t.co/q4hGEKeQIP https://t.co/OWMshjdjlz https://t.co/fTuCBfT1iq
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial, from @JAMA_current, free to read online during #ADA2022 https://t.co/ggzNuo2QcZ https://t.co/widykMlU93
https://t.co/SyIDlYChB5
RT @DrBobGabbay: Nice to see a new med for #T2D #diabetes with good effect on A1c and weight loss https://t.co/CjeVE3BkyR
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
RT @DrBobGabbay: Nice to see a new med for #T2D #diabetes with good effect on A1c and weight loss https://t.co/CjeVE3BkyR
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/UmlUzSME48
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
RT @DrBobGabbay: Nice to see a new med for #T2D #diabetes with good effect on A1c and weight loss https://t.co/CjeVE3BkyR
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
RT @DrBobGabbay: Nice to see a new med for #T2D #diabetes with good effect on A1c and weight loss https://t.co/CjeVE3BkyR
RT @DrBobGabbay: Nice to see a new med for #T2D #diabetes with good effect on A1c and weight loss https://t.co/CjeVE3BkyR
Nice to see a new med for #T2D #diabetes with good effect on A1c and weight loss https://t.co/CjeVE3BkyR
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
The SURPASS-5 Randomized Clinical Trial https://t.co/DnY7pM92wl Tirzepatide añadido a Glargina Excelentes resultados ⤵️⤵️⤵️
RT @SeguraCardio:
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
RT @DrKarlNadolsky: #tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2…
#tirzepatide + glargine resulted in outstanding weight loss and glycemic improvements in those with #ibesity and type 2 #diabetes JAMA. 2022;327(6):534-545. doi:10.1001/jama.2022.0078 https://t.co/hC10azu0Py https://t.co/zNomWMcYJ3
https://t.co/1EcKcHcWqD
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network ✅✅✅
RT @SeguraCardio:
RT @SeguraCardio:
RT @SeguraCardio:
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @SeguraCardio:
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @SeguraCardio:
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
RT @CristobMorales: https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Co…
https://t.co/7YIwZ6gIzl Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes #SURPASS5trial Orgulloso de la participación de centros Españoles en esta gran innovación @SEDiabetes @LillyES https://t.co/2LldT4yKzp
RT @SeguraCardio:
RT @SeguraCardio:
RT @SeguraCardio:
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @SeguraCardio:
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous tirzepatide, vs placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 wk. https://t.co/LlO1c0GpRr https://t.co/IqHycbTJAF
RT @JAMA_current: Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous ti…
Study found, in pts w diabetes & inadequate glycemic control despite use of insulin glargine, addition of subcutaneous tirzepatide, vs placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 wk. https://t.co/BFDnS4UTjX https://t.co/Hp3qoATtWG